Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C:
Giacomo Brisca1, Alessandro Consolaro2,3, Roberta Caorsi2
1Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Insights
Early, aggressive treatment for multisystem inflammatory syndrome in children (MIS-C) based on severity prevents ICU admission. Tailored anti-inflammatory protocols, including anti-IL-1 blockers for severe cases, improve outcomes.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Multisystem inflammatory syndrome in children (MIS-C) is a serious condition requiring prompt management.
- Understanding optimal therapeutic strategies for MIS-C is crucial for improving patient outcomes.
Purpose of the Study:
- To report the clinical, therapeutic, and outcome features of MIS-C patients treated with a severity-based protocol.
- To evaluate the effectiveness of a multistep anti-inflammatory treatment approach for MIS-C.
Main Methods:
- Observational study of 23 MIS-C patients at Gaslini Children Hospital.
- Treatment protocol stratified into four severity classes upon admission.
- Therapeutic options included IV immunoglobulin, methylprednisolone pulses, and anakinra, with escalation based on response.
Main Results:
- No patients required Intensive Care Unit (ICU) admission or mechanical ventilation.
- No inotropic drug administration was necessary.
- Early, aggressive, and tailored treatment prevented disease progression.
Conclusions:
- A severity-based, multistep anti-inflammatory treatment protocol is effective in managing MIS-C.
- Early intervention, including anti-IL-1 blockers for severe cases, can prevent severe complications and ICU admission.
Abstract:
In this observational study, we report the clinical, therapeutics and outcome features of 23 patients with multisystem inflammatory syndrome (MIS-C) who have been treated in Gaslini Children Hospital (Genoa, Italy) with a multistep antinflammatory treatment protocol, based on disease severity at admission. Patients were initially assigned to four severity classes on admission and treated accordingly. The therapeutic options ranged from IV immunoglobulin alone to a combination of IVIG plus pulses of methylprednisolone plus anakinra for patients with marked cardiac function impairment or signs of macrophage activation syndrome, with rapid treatment escalation in case of inadequate therapeutic response. With the application of this therapeutic strategy, no patient required admission to Intensive Care Unit (ICU) or invasive mechanical ventilation, and no inotropic drugs administration was required. Early aggressive treatment of MIS-C, with therapeutic interventions modulated based on the severity of clinical manifestations may help to prevent the progression of the inflammatory process and to avoid the need of admission to the ICU. A timely intervention with anti-IL-1 blockers can play a pivotal role in very severe patients that are at risk to have an incomplete response to immunoglobulins and steroids.
More Related Videos
06:04Objective Nociceptive Assessment in Ventilated ICU Patients: A Feasibility Study Using Pupillometry and the Nociceptive Flexion Reflex
Published on: July 4, 2018
08:25Polar Histogram Visualization of Acute Stress Disorder Scale Scores for Comprehensive Clinical Assessment
Published on: December 6, 2024
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Acute Coronary Syndrome V: Nursing Management
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
